Next Generation Cancer Diagnostic Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the global next generation cancer diagnostic market looks promising with opportunities in biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis. The global next generation cancer diagnostic market is expected to grow with a CAGR of 21%-23% from 2020 to 2025. The major drivers for this market are increasing prevalence of oncology diseases and growing demand for efficient cancer screening tests.
Emerging trends, which have a direct impact on the dynamics of the industry, include growing adoption of point-of-care testing and advancement in next generation sequencing technologies.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global next generation cancer diagnostic market report, please download the report brochure.
In this market, lung is the largest cancer site of next generation cancer diagnostic, whereas biomarker development is the largest application. Growth in various segments of the next generation cancer diagnostic market are given below:
The study includes trends and forecast for the global next generation cancer diagnostic market by cancer site, test purpose, test platform, application, and region as follows:
By Cancer Site [Value ($ Million) shipment analysis for 2014 – 2025]:
BladderBrainBreastColorectalCancer Of Unknown PrimaryGastricGynecologicHematologicKidneyLiverLungPan-CancerPancreaticProstateMelanomaThyroid
By Test Purpose [Value ($ Million) shipment analysis for 2014 – 2025]:
Screening/Early DetectionDiagnosisMonitoringTherapy Guidance
By Test Platform [Value ($ Million) shipment analysis for 2014 – 2025]:
Arrays/MicrofluidicsCell/EV CaptureMultiplex ConventionalPolymerase Chain Reaction (PCR)Next Generation Sequencing (NGS)
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
Biomarker DevelopmentCTC AnalysisProteomic AnalysisEpigenetic AnalysisGenetic Analysis
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North AmericaUnited StatesCanada MexicoEuropeUnited KingdomGermanyFranceAsia PacificChinaIndiaJapanThe Rest of the WorldBrazil
Some of the next generation cancer diagnostics companies profiled in this report include Cepheid, Philips, Roche, Qiagen, Novartis, Abbott, Thermo Fisher Scientific, Opko Health, Myriad Genetics, Agilent Technologies, and GE Healthcare.
Lucintel forecasts that lung cancer will remain the largest cancer site segment over the forecast period due to increasing pollution and adoption of smoking that leads to increasing cases of lung cancer.
Within this market, biomarker development will remain the largest segment by application over the forecast period due to increasing discovery and development of drugs.
North America will remain the largest region over the forecast period due to increasing investment in research and development, favorable government initiatives (such as movement for colon cancer detection), and increasing demand for personalized medicines in the region.
Features of the Global Next Generation Cancer Diagnostic Market
Market Size Estimates: Global next generation cancer diagnostic market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Global next generation cancer diagnostic market size by various segments, such as cancer site, test purpose, test platform, and application in terms of value.Regional Analysis: Global next generation cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.Growth Opportunities: Analysis of growth opportunities in different cancer sites, test purposes, test platforms, applications, and regions for the global next generation cancer diagnostic market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global next generation cancer diagnostic market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the global next generation cancer diagnostic market by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma, and thyroid), test purpose (screening/early detection, diagnosis, monitoring, and therapy guidance), test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, polymerase chain reaction (PCR), and next generation sequencing (NGS)), application (biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global next generation cancer diagnostics market?
Q.5 What are the business risks and threats to the global next generation cancer diagnostic market?
Q.6 What are the emerging trends in the next generation cancer diagnostic market and the reasons behind them?
Q.7 What are some changing demands of customers in the next generation cancer diagnostic market?
Q.8 What are the new developments in the next generation cancer diagnostic market? Which companies are leading these developments?
Q.9 Who are the major players in the next generation cancer diagnostic market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in the next generation cancer diagnostic market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global next generation cancer diagnostic market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecast, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Ventures, and Company Profiling
Market Segments Cancer Site (Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid), Test Purpose (Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance), Test Platform (Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, and PCR and NGS), and Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis)
Regional Scope North America (USA, Mexico, and Canada), Europe (UK, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
The future of the global next generation cancer diagnostic market looks promising with opportunities in biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis. The global next generation cancer diagnostic market is expected to grow with a CAGR of 21%-23% from 2020 to 2025. The major drivers for this market are increasing prevalence of oncology diseases and growing demand for efficient cancer screening tests.
Emerging trends, which have a direct impact on the dynamics of the industry, include growing adoption of point-of-care testing and advancement in next generation sequencing technologies.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global next generation cancer diagnostic market report, please download the report brochure.
In this market, lung is the largest cancer site of next generation cancer diagnostic, whereas biomarker development is the largest application. Growth in various segments of the next generation cancer diagnostic market are given below:
The study includes trends and forecast for the global next generation cancer diagnostic market by cancer site, test purpose, test platform, application, and region as follows:
By Cancer Site [Value ($ Million) shipment analysis for 2014 – 2025]:
BladderBrainBreastColorectalCancer Of Unknown PrimaryGastricGynecologicHematologicKidneyLiverLungPan-CancerPancreaticProstateMelanomaThyroid
By Test Purpose [Value ($ Million) shipment analysis for 2014 – 2025]:
Screening/Early DetectionDiagnosisMonitoringTherapy Guidance
By Test Platform [Value ($ Million) shipment analysis for 2014 – 2025]:
Arrays/MicrofluidicsCell/EV CaptureMultiplex ConventionalPolymerase Chain Reaction (PCR)Next Generation Sequencing (NGS)
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
Biomarker DevelopmentCTC AnalysisProteomic AnalysisEpigenetic AnalysisGenetic Analysis
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
North AmericaUnited StatesCanada MexicoEuropeUnited KingdomGermanyFranceAsia PacificChinaIndiaJapanThe Rest of the WorldBrazil
Some of the next generation cancer diagnostics companies profiled in this report include Cepheid, Philips, Roche, Qiagen, Novartis, Abbott, Thermo Fisher Scientific, Opko Health, Myriad Genetics, Agilent Technologies, and GE Healthcare.
Lucintel forecasts that lung cancer will remain the largest cancer site segment over the forecast period due to increasing pollution and adoption of smoking that leads to increasing cases of lung cancer.
Within this market, biomarker development will remain the largest segment by application over the forecast period due to increasing discovery and development of drugs.
North America will remain the largest region over the forecast period due to increasing investment in research and development, favorable government initiatives (such as movement for colon cancer detection), and increasing demand for personalized medicines in the region.
Features of the Global Next Generation Cancer Diagnostic Market
Market Size Estimates: Global next generation cancer diagnostic market size estimation in terms of value ($M) shipment.Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.Segmentation Analysis: Global next generation cancer diagnostic market size by various segments, such as cancer site, test purpose, test platform, and application in terms of value.Regional Analysis: Global next generation cancer diagnostic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.Growth Opportunities: Analysis of growth opportunities in different cancer sites, test purposes, test platforms, applications, and regions for the global next generation cancer diagnostic market.Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global next generation cancer diagnostic market.Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
This report answers following key questions
Q.1 What are some of the most promising potential, high-growth opportunities for the global next generation cancer diagnostic market by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma, and thyroid), test purpose (screening/early detection, diagnosis, monitoring, and therapy guidance), test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, polymerase chain reaction (PCR), and next generation sequencing (NGS)), application (biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis), and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global next generation cancer diagnostics market?
Q.5 What are the business risks and threats to the global next generation cancer diagnostic market?
Q.6 What are the emerging trends in the next generation cancer diagnostic market and the reasons behind them?
Q.7 What are some changing demands of customers in the next generation cancer diagnostic market?
Q.8 What are the new developments in the next generation cancer diagnostic market? Which companies are leading these developments?
Q.9 Who are the major players in the next generation cancer diagnostic market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in the next generation cancer diagnostic market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global next generation cancer diagnostic market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecast, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Ventures, and Company Profiling
Market Segments Cancer Site (Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid), Test Purpose (Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance), Test Platform (Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, and PCR and NGS), and Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis)
Regional Scope North America (USA, Mexico, and Canada), Europe (UK, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Next Generation Cancer Diagnostic Market Trends and Forecast
3.3: Global Next Generation Cancer Diagnostic Market by Cancer Site
3.3.1: Bladder
3.3.2: Brain
3.3.3: Breast
3.3.4: Colorectal
3.3.5: Cancer of Unknown Primary
3.3.6: Gastric
3.3.7: Gynecologic
3.3.8: Hematologic
3.3.9: Kidney
3.3.10: Liver
3.3.11: Lung
3.3.12: Pan-Cancer
3.3.13: Pancreatic
3.3.14: Prostate
3.3.15: Melanoma
3.3.16: Thyroid
3.4: Global Next Generation Cancer Diagnostic Market by Test Purpose
3.4.1: Screening/Early Detection
3.4.2: Diagnosis
3.4.3: Monitoring
3.4.4: Therapy Guidance
3.5: Global Next Generation Cancer Diagnostic Market by Test Platform
3.5.1: Arrays/Microfluidics
3.5.2: Cell/EV Capture
3.5.3: Multiplex Conventional
3.5.4: Polymerase Chain Reaction (PCR)
3.5.5: Next Generation Sequencing (NGS)
3.6: Global Next Generation Cancer Diagnostic Market by Application
3.6.1: Biomarker Development
3.6.2: CTC Analysis
3.6.3: Proteomic Analysis
3.6.4: Epigenetic Analysis
3.6.5: Genetic Analysis
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Next Generation Cancer Diagnostic Market by Region
4.2: North American Next Generation Cancer Diagnostic Market
4.2.1: Market by Cancer Site: Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid
4.2.2: Market by Test Purpose: Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance
4.2.3: Market by Test Platform: Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, Polymerase Chain Reaction (PCR), and Next Generation Sequencing (NGS)
4.2.4: Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis
4.2.5: The United States Next Generation Cancer Diagnostic Market
4.2.6: The Canadian Next Generation Cancer Diagnostic Market
4.2.7: The Mexican Next Generation Cancer Diagnostic Market
4.3: European Next Generation Cancer Diagnostic Market
4.3.1: Market by Cancer Site: Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid
4.3.2: Market by Test Purpose: Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance
4.3.3: Market by Test Platform: Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, Polymerase Chain Reaction (PCR), and Next Generation Sequencing (NGS)
4.3.4: Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis
4.3.5: The Next Generation Cancer Diagnostic Market of the United Kingdom
4.3.6: The German Next Generation Cancer Diagnostic Market
4.3.7: The French Next Generation Cancer Diagnostic Market
4.4: APAC Next Generation Cancer Diagnostic Market
4.4.1: Market by Cancer Site: Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid
4.4.2: Market by Test Purpose: Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance
4.4.3: Market by Test Platform: Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, Polymerase Chain Reaction (PCR), and Next Generation Sequencing (NGS)
4.4.4: Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis
4.4.5: The Chinese Next Generation Cancer Diagnostic Market
4.4.6: The Indian Next Generation Cancer Diagnostic Market
4.4.7: The Japanese Next Generation Cancer Diagnostic Market
4.5: ROW Next Generation Cancer Diagnostic Market
4.5.1: Market by Cancer Site: Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid
4.5.2: Market by Test Purpose: Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance
4.5.3: Market by Test Platform: Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, Polymerase Chain Reaction (PCR), and Next Generation Sequencing (NGS)
4.5.4: Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis
4.5.5: Brazilian Next Generation Cancer Diagnostic Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Cancer Site
7.1.2: Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Test Purpose
7.1.3: Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Test Platform
7.1.4: Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Application
7.1.5: Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Region
7.2: Emerging Trends in the Global Next Generation Cancer Diagnostic Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Next Generation Cancer Diagnostic Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Next Generation Cancer Diagnostic Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Cepheid
8.2: Koninklijke Philips N.V.
8.3: F. Hoffmann-La Roche Ltd.
8.4: Qiagen; Novartis AG
8.5: Abbott
8.6: Therm Fisher Scientific, Inc.
8.7: Opk Health, Inc.
8.8: Myriad Genetics, Inc.
8.9: Agilent Technologies
8.10: GE Healthcare
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Next Generation Cancer Diagnostic Market Trends and Forecast
3.3: Global Next Generation Cancer Diagnostic Market by Cancer Site
3.3.1: Bladder
3.3.2: Brain
3.3.3: Breast
3.3.4: Colorectal
3.3.5: Cancer of Unknown Primary
3.3.6: Gastric
3.3.7: Gynecologic
3.3.8: Hematologic
3.3.9: Kidney
3.3.10: Liver
3.3.11: Lung
3.3.12: Pan-Cancer
3.3.13: Pancreatic
3.3.14: Prostate
3.3.15: Melanoma
3.3.16: Thyroid
3.4: Global Next Generation Cancer Diagnostic Market by Test Purpose
3.4.1: Screening/Early Detection
3.4.2: Diagnosis
3.4.3: Monitoring
3.4.4: Therapy Guidance
3.5: Global Next Generation Cancer Diagnostic Market by Test Platform
3.5.1: Arrays/Microfluidics
3.5.2: Cell/EV Capture
3.5.3: Multiplex Conventional
3.5.4: Polymerase Chain Reaction (PCR)
3.5.5: Next Generation Sequencing (NGS)
3.6: Global Next Generation Cancer Diagnostic Market by Application
3.6.1: Biomarker Development
3.6.2: CTC Analysis
3.6.3: Proteomic Analysis
3.6.4: Epigenetic Analysis
3.6.5: Genetic Analysis
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Next Generation Cancer Diagnostic Market by Region
4.2: North American Next Generation Cancer Diagnostic Market
4.2.1: Market by Cancer Site: Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid
4.2.2: Market by Test Purpose: Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance
4.2.3: Market by Test Platform: Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, Polymerase Chain Reaction (PCR), and Next Generation Sequencing (NGS)
4.2.4: Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis
4.2.5: The United States Next Generation Cancer Diagnostic Market
4.2.6: The Canadian Next Generation Cancer Diagnostic Market
4.2.7: The Mexican Next Generation Cancer Diagnostic Market
4.3: European Next Generation Cancer Diagnostic Market
4.3.1: Market by Cancer Site: Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid
4.3.2: Market by Test Purpose: Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance
4.3.3: Market by Test Platform: Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, Polymerase Chain Reaction (PCR), and Next Generation Sequencing (NGS)
4.3.4: Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis
4.3.5: The Next Generation Cancer Diagnostic Market of the United Kingdom
4.3.6: The German Next Generation Cancer Diagnostic Market
4.3.7: The French Next Generation Cancer Diagnostic Market
4.4: APAC Next Generation Cancer Diagnostic Market
4.4.1: Market by Cancer Site: Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid
4.4.2: Market by Test Purpose: Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance
4.4.3: Market by Test Platform: Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, Polymerase Chain Reaction (PCR), and Next Generation Sequencing (NGS)
4.4.4: Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis
4.4.5: The Chinese Next Generation Cancer Diagnostic Market
4.4.6: The Indian Next Generation Cancer Diagnostic Market
4.4.7: The Japanese Next Generation Cancer Diagnostic Market
4.5: ROW Next Generation Cancer Diagnostic Market
4.5.1: Market by Cancer Site: Bladder, Brain, Breast, Colorectal, Cancer of Unknown Primary, Gastric, Gynecologic, Hematologic, Kidney, Liver, Lung, Pan-Cancer, Pancreatic, Prostate, Melanoma, and Thyroid
4.5.2: Market by Test Purpose: Screening/Early Detection, Diagnosis, Monitoring, and Therapy Guidance
4.5.3: Market by Test Platform: Arrays/Microfluidics, Cell/EV Capture, Multiplex Conventional, Polymerase Chain Reaction (PCR), and Next Generation Sequencing (NGS)
4.5.4: Market by Application: Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, and Genetic Analysis
4.5.5: Brazilian Next Generation Cancer Diagnostic Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Cancer Site
7.1.2: Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Test Purpose
7.1.3: Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Test Platform
7.1.4: Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Application
7.1.5: Growth Opportunities for the Global Next Generation Cancer Diagnostic Market by Region
7.2: Emerging Trends in the Global Next Generation Cancer Diagnostic Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Next Generation Cancer Diagnostic Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Next Generation Cancer Diagnostic Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Cepheid
8.2: Koninklijke Philips N.V.
8.3: F. Hoffmann-La Roche Ltd.
8.4: Qiagen; Novartis AG
8.5: Abbott
8.6: Therm Fisher Scientific, Inc.
8.7: Opk Health, Inc.
8.8: Myriad Genetics, Inc.
8.9: Agilent Technologies
8.10: GE Healthcare
